Evidence map›Paper›PMID 37702905›Full record

ArticleAnnals of surgical oncology2023

Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms.

Michael G White, Neal Bhutiani, Beth A Helmink, Melissa Taggart, Wai Chin Foo, Paul F Mansfield, Keith F Fournier, Christopher P Scally

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michael G WhiteDepartment of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neal BhutianiDepartment of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beth A HelminkUnit 1484, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melissa TaggartDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wai Chin FooDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul F MansfieldUnit 1484, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keith F FournierUnit 1484, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher P ScallyUnit 1484, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cscally@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeterogenous nomenclature describing appendiceal neoplasms has added to uncertainty around their appropriate treatment. Although a recent consensus has established the term low-grade appendiceal neoplasm (LAMN), we hypothesize that significant variation remains in the treatment of LAMNs.

methodsWe retrospectively reviewed our prospectively maintained appendiceal registry, identifying patients with LAMNs from 2009 to 2019. We assessed variability in treatment, including whether patients underwent colectomy, spread of disease at presentation, and long-term outcomes.

resultsOf 136 patients with LAMNs, 88 (35%) presented with localized disease and 48 (35%) with disseminated peritoneal disease. Median follow-up was 2.9 years (IQR 1.9-4.4), and 120 (88%) patients underwent pre-referral surgery. Among 26 pre-referral colectomy patients, 23 (88%) were performed for perceived oncologic need/nodal evaluation; no nodal metastases were identified. In patients with resected LAMNs without radiographic evidence of disseminated disease, 41 (47%) underwent second look diagnostic laparoscopy (DL) to evaluate for occult metastases. No peritoneal metastases were identified. Patients with disseminated disease were treated with cytoreductive surgery/heated intraperitoneal chemotherapy (CRS/HIPEC). For patients undergoing CRS/HIPEC, 5-year recurrence-free survival was 94% (95% CI 81-98%). For patients with localized disease, 5-year RFS was 98% (95% CI 85-99%).

conclusionsSignificant variation exists in treatment patterns for LAMNs, particularly prior to referral to a high-volume center. Patients frequently underwent colectomy without apparent oncologic benefit. In the current era of high-quality cross sectional imaging, routine use of DL has low yield and is not recommended. Recurrence in this population is rare, and low-intensity surveillance can be offered. Overall prognosis is excellent, even with peritoneal disease.

Indexed as

Appendiceal NeoplasmsHyperthermia, InducedPeritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCytoreduction Surgical ProceduresHumansPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID37702905
OpenAlexW4386704186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.